Dr. Robert J. Behrens, MD

Dr. Behrens practices at University of Iowa Health Care Medical Center in Iowa City, Iowa, part of The University of Iowa.

Dr. Behrens' NPI, 1215999800, was assigned on April 6, 2006. Dr. Behrens graduated from University of Iowa, RJ & L Carver College of Medicine in 1997. Dr. Behrens holds Iowa license MD-34946.

Dr. Behrens' primary practice is University of Iowa Health Care Medical Center, at 200 Hawkins Drive, Iowa City, IA 52242 in Johnson County. The practice phone is (319) 356-1616.

Dr. Behrens' primary practice is University of Iowa Health Care Medical Center in Iowa City, Iowa, part of The University of Iowa. Dr. Behrens is also affiliated with UnityPoint Health - Iowa Methodist Medical Center. The medical group on file is Scanlan Center for School Mental Health Clinic. Dmand AI also links Dr. Behrens to 3 more hospitals, 3 medical groups, 2 hospices and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Behrens practices, 8 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Behrens' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Behrens is licensed in Iowa.

CMS data shows 387,870 Medicare services from Dr. Behrens across 80 procedure codes in 2024, for 908 Medicare patients. Medicare paid $7,029,285 for them.

CMS counts 908 Medicare patients who saw Dr. Behrens in 2024. The largest group is 65 to 74, with 416 patients. 73% of them have high blood pressure, and 72% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Behrens' median patient age at 73, with 53% women.

In 2024, Dr. Behrens wrote 1,740 Medicare Part D claims for 276 patients. 82% of them were for generic drugs. CMS names the drug for 1,505 of them, across 39 drugs with 11 or more claims each, at $3,897,523 in total drug cost. In 2023, CMS named 1,354 claims across 35 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Behrens for performance year 2024, reported through an alternative payment model (APM). Dr. Behrens accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 18 papers to Dr. Behrens, published from 2011 to 2025. 2012 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma and Paclitaxel. Dr. Behrens has published most often in Cancer. Dr. Behrens' most frequent co-authors are Steven R. Alberts, MD, George Paik Kim, MD and Charles L. Loprinzi, MD.

Dmand AI links Dr. Behrens to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Carcinoma, Transitional Cell. National Cancer Institute (NCI) sponsors the most, 10.

CMS Open Payments shows 5 general payments to Dr. Behrens from 5 drug and device companies from 2020 to 2023. Food and beverage make up the largest share, 93% of the total. ADC Therapeutics America, Inc. paid the most, $125.

Dr. Behrens graduated from University of Iowa, RJ & L Carver College of Medicine in 1997.